About the Company
We do not have any company description for Entera Bio Ltd. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Entera Bio Ltd.
Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should ...
Entera Bio Ltd. will be looking to display strength as it nears its next earnings release. On that day, Entera Bio Ltd. is projected to report earnings of -$0.12 per share, which would represent a ...
Entera Bio Ltd.: Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignifi ...
Entera Bio Announces Full Year 2024 Financial Results and Provides ...
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...
Entera Bio Ltd. to Present at Oppenheimer 35th Annual ... - Nasdaq
Entera Bio Ltd. will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference from February 11-12, 2025, and is scheduled to present on February 11 at 12:40 PM ET.
Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You ...
Entera Bio Ltd. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...
Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey ...
Our goal is for Entera Bio’s EB613 oral PTH to be that product. We expect to complete patient enrollment in our Phase 2 study of EB613 in the third quarter of 2020 with a goal of moving into ...
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis ...
Entera Bio Announces Full Year 2023 Financial Results and Provides ...
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results ...
Similar Companies
Loading the latest forecasts...